EGFR and breast cancer: The application of this kind of digital genomic assay that allows discrimination of rare mutant variants in ctDNA has been reported in a wide range of cancers: for example, noninvasive detection of epidermal growth factor receptor (EGFR)- mutants in lung cancer [9] and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-mutants in breast cancer [10], and many other kinds of genetic-mutants in corresponding tumors.